It's a little from Column A and little from Column B – and nothing from Column C (for controversial) – for what looks to be the final version of the 2017 user fee reauthorization legislation.
User Fee Reauthorization: 'Pre-Conferenced' Bill Aims For Quick Passage
'Clean' bill includes expanded access language from Senate, generic review revisions from House as legislators hope for enactment this month.
More from Legislation
More from Pink Sheet
• By
The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.